Artelo Biosciences - initial Dream study results anticipated in Q4 2026

Artelo Biosciences, Inc. (Nasdaq: ARTL) is preparing to advance its clinical pipeline with multiple key milestones expected through 2026 and beyond. The company, which focuses on modulating lipid-signaling pathways to develop treatments for conditions including cancer, pain, and neurological disorders, has outlined progress across its lead programs, including ART26.12 and ART27.13, as well as its preclinical candidate ART12.11.

ART26.12, the company’s lead FABP5 inhibitor, is progressing through Phase 1 studies. Following positive first-in-human Phase 1 single ascending dose and preliminary food-effect data, Artelo is preparing to initiate the multiple ascending dose study, with enrollment anticipated to begin in the fourth quarter of 2026. The compound has demonstrated a favorable safety profile and predictable pharmacokinetics, supporting its potential as a non-opioid, non-steroidal analgesic for pain management.

Meanwhile, ART27.13, a peripherally selective synthetic cannabinoid receptor agonist, continues to show promise in addressing cancer-related anorexia and cachexia. Encouraging interim Phase 2 CAReS data demonstrated improvements in body weight, lean body mass, and physical activity, with a favorable tolerability profile. The compound is also being explored for potential use as a GLP-1 companion therapy and in a third-party funded glaucoma study.

In addition to these developments, Artelo has strengthened its balance sheet through recent capital raises, providing a significant cash runway to advance its clinical programs. The company is also benefiting from third-party clinical research grants, including the fully funded Phase 2 glaucoma study with ART27.13.

Artelo’s financial results for the first quarter of 2026 reflect ongoing investment in its pipeline. Research and development expenses were $0.8 million for the quarter, compared to $1.4 million in the same period in 2025. General and administrative expenses rose to $1.9 million, compared to $1.0 million in the prior year. As of March 31, 2026, the company reported cash and investments totaling $10.3 million.

Looking ahead, Artelo remains focused on advancing its clinical programs toward key inflection points, with the potential for meaningful value creation through upcoming milestones and strategic partnerships.